16 Result(s)

Article

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure across psoriatic arthritis (PsA),...

Gerd R. Burmester, Jayne Stigler, Andrea Rubbert-Roth… in Rheumatology and Therapy (2024)

Article

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis

This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated wit...

Andrea Rubbert-Roth, Adriana M. Kakehasi, Tsutomu Takeuchi… in Rheumatology and Therapy (2024)

Article

Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry

As anaemia represents a biomarker for increased radiographic damage in rheumatoid arthritis, we aimed to investigate whether it independently predicts spinal radiographic progression in axial spondyloarthritis...

Raphael Micheroli, Seraphina Kissling, Kristina Bürki… in Clinical Rheumatology (2023)

Article

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies

We sought to identify and compare treatment response groups based on individual patient responses (rather than group mean response) over time on the Clinical Disease Activity Index (CDAI) for rheumatoid arthri...

Peter C. Taylor, Yun-Fei Chen, Janet Pope, Michael Weinblatt… in Rheumatology and Therapy (2023)

Article

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab

Anemia is common in patients with rheumatoid arthritis (RA). Higher hemoglobin (Hb) levels may be associated with better clinical outcomes and patient-reported outcomes (PROs). To assess this hypothesis, we co...

Andrea Rubbert-Roth, Daniel E. Furst, Stefano Fiore… in Arthritis Research & Therapy (2022)

Article

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials

This integrated analysis describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, at 15 and 30 mg once daily for up to 3 years of exposure in patients with active psoriatic arthritis (PsA)...

Gerd R. Burmester, Kevin Winthrop, Ricardo Blanco, Peter Nash… in Rheumatology and Therapy (2022)

Article

Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

Markus Rehberg, Clemens Giegerich, Amy Praestgaard… in Rheumatology and Therapy (2021)

Article

Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

In rheumatoid arthritis, time spent using ineffective medications may lead to irreversible disease progression. Despite availability of targeted treatments, only a minority of patients achieve sustained remiss...

Markus Rehberg, Clemens Giegerich, Amy Praestgaard… in Rheumatology and Therapy (2021)

Article

A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases

Tocilizumab (TCZ) is the first humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody approved for the treatment of patients with rheumatoid arthritis (RA), Castleman’s disease, polyarticular and sys...

Andrea Rubbert-Roth, Daniel E. Furst, Jan Michael Nebesky… in Rheumatology and Therapy (2018)

Article

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Methotrexate (MTX) remains the anchor drug in rheumatoid arthritis (RA) treatment, but is poorly tolerated or contraindicated in some patients. There is a wealth of data supporting the use of abatacept in comb...

Rieke Alten, Harald Burkhardt, Eugen Feist, Klaus Krüger… in Arthritis Research & Therapy (2018)

Article

Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients

The aim of this study was to evaluate the safety and efficacy of rituximab (RTX) in a large cohort of patients with rheumatoid arthritis in routine care, and to monitor changes in daily practice since the intr...

Joerg Wendler, Gerd R Burmester, Helmut Sörensen… in Arthritis Research & Therapy (2014)

Article

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to ...

Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops… in Arthritis Research & Therapy (2011)

Article

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

Conventional disease-modifying antirheumatic drugs such as methotrexate are the mainstay of treatment for rheumatoid arthritis. More recently, biologic agents such as etanercept, infliximab and adalimumab, whi...

Andrea Rubbert-Roth, Axel Finckh in Arthritis Research & Therapy (2009)